Results 141 to 150 of about 65,496 (283)

Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Options

open access: yesEffective Pharmacotherapy
Dipeptidyl peptidase 4 inhibitors are a new innovative class of glucose-lowering drugs. The drugs belong to the group of incretin mimetics, prolonging the action of their own incretins. Since 2007, the list of proposed dipeptidyl peptidase 4 inhibitors has expanded significantly and significant experience in their use has accumulated.
S.V. Podachina, I.V. Soloviova
openaire   +1 more source

Effect of switching from intermittently scanned continuous glucose monitoring to FreeStyle Libre 2 with real‐time continuous glucose monitoring and alert functionality

open access: yesJournal of Diabetes Investigation, EarlyView.
Transitioning from FSL to FSL2 with rtCGM function improved sensor usage and glycemic control, particularly in patients with Type 1 diabetes. The duration required for improvement in continuous glucose monitoring‐related parameters varied by diabetes type, with early improvements observed in Type 1 diabetes and gradual improvements in Type 2 diabetes ...
Keiji Sugai   +3 more
wiley   +1 more source

Efficacy of probiotics (Bifidobacterium bifidum G9‐1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open‐label, single‐arm study (BIRDIE study)

open access: yesJournal of Diabetes Investigation, EarlyView.
Bifidobacterium bifidum G9‐1 improved stool form, defecation frequency, and Quality of Life in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation. ABSTRACT Introduction Although constipation is a major complication of type 2 diabetes mellitus and chronic kidney disease, evidence for its treatment in these ...
Fuki Ikeda   +10 more
wiley   +1 more source

Endogenous GIP signaling is indispensable for DPP‐4 inhibitor‐mediated metabolic control in mice

open access: yesJournal of Diabetes Investigation, EarlyView.
This study reveals that the metabolic benefits of DPP‐4 inhibitors, including improved glucose tolerance and reduced body weight, are completely abolished in GIP receptor‐deficient mice. These findings establish that endogenous GIP signaling, rather than GLP‐1, is the indispensable key player for the efficacy of this drug class.
Saki Kubota‐Okamoto   +17 more
wiley   +1 more source

Serum dipeptidyl peptidase-4 in chronic liver disease patients with osteoporosis

open access: yesEgyptian Liver Journal
Background and aim Fibrosis and cirrhosis are the results of the progressive degradation and regeneration of the liver parenchyma in chronic liver disease (CLD).
Nashwa Farouk Mohamed Elmetwaly   +4 more
doaj   +1 more source

Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice [PDF]

open access: yes, 2021
Cayasso, Mayella   +6 more
core   +1 more source

Heart failure and dipeptidyl peptidase‐4 inhibitors [PDF]

open access: yesEuropean Journal of Heart Failure, 2014
Henry, Krum   +3 more
openaire   +2 more sources

Engineering Marker‐Free Lettuce Chloroplast Genome to Express Functional Glucagon‐Like Peptide‐1 Receptor Agonists Exenatide and Lixisenatide

open access: yesPlant Biotechnology Journal, EarlyView.
Engineering of marker‐free lettuce chloroplast genome to express CTB‐Exenatide and CTB‐Lixisenatide for oral delivery. Upper panel: Chemically synthesised exenatide or lixisenatide require expensive production, purification, refrigeration and invasive delivery methods.
Rahul Singh, Henry Daniell
wiley   +1 more source

Biological definition of periodontal diseases: A historical review of host‐response diagnostics and their implications for disease classification

open access: yesPeriodontology 2000, EarlyView.
Abstract Background Understanding periodontal diseases through a biological lens has been a central aim in periodontal research. Visionary pioneers in the field established the foundations of our knowledge, providing invaluable insights into disease mechanisms and progression.
Nagihan Bostanci   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy